Skip to main content

Advertisement

SpringerLink
Log in

Induction of iodide uptake in transformed thyrocytes: a compound screening in cell lines

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

Retinoic acid presently is the most advanced agent able to improve the efficacy of radioiodine therapy in differentiated thyroid carcinoma. In order to identify compounds with higher efficacy a panel of pharmacologically well-characterized compounds with antitumour action in solid cancer cell lines was screened.

Methods

The effects of the compounds on iodide uptake, cell number, proliferation and apoptosis were evaluated.

Results

In general, compounds were more effective in cell lines derived from more aggressive tumours. The effectiveness in terms of number of responsive cell lines and maximal increase in iodide uptake achieved decreased in the order: APHA > valproic acid ≈ sirolimus ≈ arsenic trioxide > retinoic acid ≈ lovastatin > apicidine ≈ azacytidine ≈ retinol ≈ rosiglitazone ≈ bortezomib.

Conclusion

We hypothesize that testing of cells from primary tumours or metastases in patients may be a way to identify compounds with optimum therapeutic efficacy for individualized treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 2006;295:2164–7.

    Article  PubMed  CAS  Google Scholar 

  2. Lubina A, Cohen O, Barchana M, Liphshiz I, Vered I, Sadetzki S, Karasik A. Time trends of incidence rates of thyroid cancer in Israel: what might explain the sharp increase. Thyroid 2006;16:1033–40.

    Article  PubMed  Google Scholar 

  3. Kebebew E, Peng M, Reiff E, Treseler P, Woeber KA, Clark OH, et al. A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer. Surgery 2006;140:960–6.

    Article  PubMed  Google Scholar 

  4. Liu YY, Stokkel MP, Pereira AM, Corssmit EP, Morreau HA, Romijn JA, et al. Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma. Eur J Endocrinol. 2006;154:525–31.

    Article  PubMed  CAS  Google Scholar 

  5. Zhang Y, Jia S, Liu Y, Li B, Wang Z, Lu H, et al. A clinical study of all-trans-retinoid-induced differentiation therapy of advanced thyroid cancer. Nucl Med Commun. 2007;28:251–5.

    Article  PubMed  CAS  Google Scholar 

  6. Tepmongkol S, Keelawat S, Honsawek S, Ruangvejvorachai P. Rosiglitazone effect on radioiodine uptake in thyroid carcinoma patients with high thyroglobulin but negative total body scan: a correlation with the expression of peroxisome proliferator-activated receptor-gamma. Thyroid 2008;18:697–704.

    Article  PubMed  CAS  Google Scholar 

  7. Catalano M, Fortunati N, Pugliese M, Costantino L, Poli R, Bosco O, et al. Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab. 2005;90:1383–9.

    Article  PubMed  CAS  Google Scholar 

  8. Fortunati N, Catalano M, Arena K, Brignardello E, Piovesan A, Boccuzzi G. Valproic acid induces the expression of the Na+/I- symporter and iodine uptake in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab. 2004;89:1006–9.

    Article  PubMed  CAS  Google Scholar 

  9. Furuya F, Shimura H, Suzuki H, Taki K, Ohta K, Haraguchi K, et al. Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin. Endocrinology 2004;145:2865–75.

    Article  PubMed  CAS  Google Scholar 

  10. Aparicio A, Weber J. Review of the clinical experience with 5-azacytidine and 5-aza-2′-deoxycytidine in solid tumors. Curr Opin Investig Drugs. 2002;3:627–3.

    PubMed  CAS  Google Scholar 

  11. Provenzano MJ, Fitzgerald MP, Krager K, Domann FE. Increased iodine uptake in thyroid carcinoma after treatment with sodium butyrate and decitabine (5-Aza-dC). Otolaryngol Head Neck Surg. 2007;137:722–8.

    Article  PubMed  Google Scholar 

  12. Park EY, Wilder ET, Lane MA. Retinol inhibits the invasion of retinoic acid-resistant colon cancer cells in vitro and decreases matrix metalloproteinase mRNA, protein, and activity levels. Nutr Cancer. 2007;57:66–77.

    PubMed  CAS  Google Scholar 

  13. Knox JJ, Siu LL, Chen E, Dimitroulakos J, Kamel-Reid S, Moore MJ, et al. A phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix. Eur J Cancer. 2005;41:523–30.

    Article  PubMed  CAS  Google Scholar 

  14. Mitsiades CS, McMillin D, Kotoula V, Poulaki V, McMullan C, Negri J, et al. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. J Clin Endocrinol Metab. 2006;91:4013–21.

    Article  PubMed  CAS  Google Scholar 

  15. Cho D, Signoretti S, Regan M, Mier JW, Atkins MB. The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin Cancer Res. 2007;13:758s–63s.

    Article  PubMed  CAS  Google Scholar 

  16. Ai Z, Lu W, Ton S, Liu H, Sou T, Shen Z, et al. Arsenic trioxide-mediated growth inhibition in gallbladder carcinoma cells via down-regulation of cyclin D1 transcription mediated by Sp1 transcription factor. Biochem Biophys Res Commun. 2007;360:684–9.

    Article  PubMed  CAS  Google Scholar 

  17. Baj G, Arnulfo A, Deaglio S, Mallone R, Vigone A, De Cesaris MG, et al. Arsenic trioxide and breast cancer: analysis of the apoptotic, differentiative and immunomodulatory effects. Breast Cancer Res Treat. 2002;3:61–73.

    Article  Google Scholar 

  18. Fröhlich E, Czarnocka B, Brossart P, Wahl R. Antitumor effects of arsenic trioxide in transformed human thyroid cells. Thyroid 2008;18:1183–93.

    Article  PubMed  CAS  Google Scholar 

  19. Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer. 2006;6:292–306.

    Article  PubMed  CAS  Google Scholar 

  20. Salvatore G, Carlomagno F, Santoro M. Pros and cons of cellular studies in developing new drugs for thyroid cancers. Thyroid 2008;18:819–22.

    Article  PubMed  Google Scholar 

  21. Herrera MF, Hay ID, Wu PS, Goellner JR, Ryan JJ, Ebersold JR, et al. Hurthle cell (oxyphilic) papillary thyroid carcinoma: a variant with more aggressive biologic behavior. World J Surg. 1992;16:669–74.

    Article  PubMed  CAS  Google Scholar 

  22. DrugLib.com. Avandia (rosiglitazone maleate) – clinical pharmacology. http://www.druglib.com/druginfo/avandia/pharmacology/. Accessed 10 Dec 2008

  23. Thibault A, Samid D, Tompkins AC, Figg WD, Cooper MR, Hohl RJ, et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res. 1996;2:483–91.

    PubMed  CAS  Google Scholar 

  24. Blomhoff R, Beckman-Sundh U, Brot C, Solvoll K, Steingrimdóttir L, Carlsen MH. Health risks related to high intake of preformed retinol (vitamin A) in the Nordic countries. TemaNord 2003:502. ISBN: 92-893-0860-5. www.blomhoff.no/pdf%20filer/Vitamin%20A%20toxicity.pdf. Accessed 11 Dec 2008.

  25. Coelho S, Vaisman M, Carvalho D. Tumour re-differentiation effect of retinoic acid: a novel therapeutic approach for advanced thyroid cancer. Curr Pharm Des. 2005;11:2525–31.

    Article  PubMed  CAS  Google Scholar 

  26. Coelho S, Corbo R, Buescu A, Carvalho D, Vaisman M. Retinoic acid in patients with radioiodine non-responsive thyroid carcinoma. J Endocrinol Invest. 2004;27:334–9.

    PubMed  CAS  Google Scholar 

  27. Simon D, Korber C, Krausch M, Segering J, Groth P, Gorges R, et al. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. Eur J Nucl Med Mol Imaging. 2002;29:775–82.

    Article  PubMed  CAS  Google Scholar 

  28. Kitazono M, Robey R, Zhan Z, Sarlis N, Skarulis M, Aikou T, et al. Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(−) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab. 2001;86:3430–35.

    Article  PubMed  CAS  Google Scholar 

  29. Ohta K, Endo T, Haraguchi K, Hershman J, Onaya T. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab. 2001;86:2170–7.

    Article  PubMed  CAS  Google Scholar 

  30. van Herle AJ, Agatep ML, Padua DN III, Totanes TL, Canlapan DV, van Herle HML, et al. Effects of 13 cis-retinoic acid on growth and differentiation of human follicular carcinoma cells (UCLA RO 82 W-1) in vitro. J Clin Endocrinol Metab. 1990;71:755–63.

    Article  PubMed  Google Scholar 

  31. van Staveren WC, Solis DW, Delys L, Duprez L, Andry G, Franc B, et al. Human thyroid tumor cell lines derived from different tumor types present a common dedifferentiated phenotype. Cancer Res. 2007;67:8113–20.

    Article  PubMed  Google Scholar 

  32. Xu J, Moatamed F, Caldwell JS, Walker JR, Kraiem Z, Taki K, et al. Enhanced expression of nicotinamide N-methyltransferase in human papillary thyroid carcinoma cells. J Clin Endocrinol Metab. 2003;88:4990–6.

    Article  PubMed  CAS  Google Scholar 

  33. von Wangenheim KH, Peterson HP. Control of cell proliferation by progress in differentiation: clues to mechanisms of aging, cancer causation and therapy. J Theor Biol. 1998;193:663–78.

    Article  Google Scholar 

  34. Bruserud O, Gjertsen BT, Huang T. Induction of differentiation and apoptosis – a possible strategy in the treatment of adult acute myelogenous leukemia. Oncologist 2000;5:454–62.

    Article  PubMed  CAS  Google Scholar 

  35. Frohlich E, Macchicao F, Wahl R. Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture. Endocr Relat Cancer. 2005;12:1–13.

    Article  CAS  Google Scholar 

  36. Schmutzler C. Regulation of the sodium/iodide symporter by retinoids – a review. Exp Clin Endocrinol Diabetes. 2001;109:41–4.

    Article  PubMed  CAS  Google Scholar 

  37. Gillam MP, Sidhaye AR, Lee EJ, Rutishauser J, Stephan CW, Kopp P. Functional characterization of pendrin in a polarized cell system. Evidence for pendrin-mediated apical iodide efflux. J Biol Chem. 2004;279:13004–10.

    Article  PubMed  CAS  Google Scholar 

  38. Rillema JA, Hill MA. Pendrin transporter carries out iodide uptake into MCF-7 human mammary cancer cells. Exp Biol Med. (Maywood) 2003;228:1078–82.

    CAS  Google Scholar 

  39. Rousset B. How iodide reaches its site of utilisation in the thyroid gland – involvement of solute carrier 26A4 (pendrin) and solute carrier 5A8 (apical iodide transporter). In: Hughes T, Dunn C, McCulloch A, editors. European Endocrine Disease 2007. London: Touch Briefings; 2007. p. 81–3.

    Google Scholar 

  40. Brabant G, Maenhaut C, Kohrle J, Scheumann G, Dralle H, Hoang-Vu C, et al. Human thyrotropin receptor gene: expression in thyroid tumors and correlation to markers of thyroid differentiation and dedifferentiation. Mol Cell Endocrinol. 1991;82:R7–12.

    Article  PubMed  CAS  Google Scholar 

  41. Kogai T, Taki K, Brent GA. Enhancement of sodium/iodide symporter expression in thyroid and breast cancer. Endocr Relat Cancer. 2006;13:797–826.

    Article  PubMed  CAS  Google Scholar 

  42. Hoelting T, Tezelman S, Siperstein AE, Duh QY, Clark OH. Biphasic effects of thyrotropin on invasion and growth of papillary and follicular thyroid cancer in vitro. Thyroid 1995;5:35–40.

    Article  PubMed  CAS  Google Scholar 

  43. Zielke A, Hoffmann S, Plaul U, Duh QY, Clark OH, Rothmund M. Pleiotropic effects of thyroid stimulating hormone in a differentiated thyroid cancer cell line. Studies on proliferation, thyroglobulin secretion, adhesion, migration and invasion. Exp Clin Endocrinol Diabetes. 1999;107:361–9.

    PubMed  CAS  Google Scholar 

  44. Demeure MJ, Doffek KM, Wilson SD. Defective thyrotropin receptor G-protein cyclic adenosine monophosphate signaling mechanism in the FTC human follicular thyroid cancer cell line. Surgery 1997;122:1195–201.

    Article  PubMed  CAS  Google Scholar 

  45. Kimura H, Yamashita S, Namba H, Usa T, Fujiyama K, Tsuruta M, et al. Impairment of the TSH signal transduction system in human thyroid carcinoma cells. Exp Cell Res. 1992;203:402–6.

    Article  PubMed  CAS  Google Scholar 

  46. Kebebew E, Wong MG, Siperstein AE, Duh QY, Clark OH. Phenylacetate inhibits growth and vascular endothelial growth factor secretion in human thyroid carcinoma cells and modulates their differentiated function. J Clin Endocrinol Metab. 1999;84:2840–7.

    Article  PubMed  CAS  Google Scholar 

  47. Meireles AM, Preto A, Rocha AS, Rebocho AP, Maximo V, Pereira-Castro I, et al. Molecular and genotypic characterization of human thyroid follicular cell carcinoma-derived cell lines. Thyroid 2007;17:707–15.

    Article  PubMed  CAS  Google Scholar 

  48. Schmutzler C, Hoang-Vu C, Ruger B, Kohrle J. Human thyroid carcinoma cell lines show different retinoic acid receptor repertoires and retinoid responses. Eur J Endocrinol. 2004;150:547–56.

    Article  PubMed  CAS  Google Scholar 

  49. Clinckspoor I, Verlinden L, Verstuyf M, Bouillon R, Decallonne B. Effects of 1,25(OH)2D3 and analog WY1112 on proliferation and differentiation of FRO cells. Horm Res. 2007;68(Suppl 3):32.

    Google Scholar 

  50. Spitzweg C, Heufelder AE. The sodium iodide symporter: its emerging relevance to clinical thyroidology. Eur J Endocrinol. 1998;138:374–5.

    Article  PubMed  CAS  Google Scholar 

  51. Woyach JA, Kloos RT, Ringel MD, Arbogast D, Collamore M, Zwiebel JA, et al. Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. J Clin Endocrinol Metab. 2008; Oct.14 [Epub ahead of print].

  52. Laboratory Corporation of America. Valproic acid (Depakote®), serum. Laboratory Corporation of America; 2007. http://www.labcorp.com/datasets/labcorp/html/chapter/mono/td024600.htm. Accessed 11 Dec 2008.

  53. Appleton K, Mackay HJ, Judson I, Plumb JA, McCormick C, Strathdee G, et al. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol. 2007;25:4603–9.

    Article  PubMed  CAS  Google Scholar 

  54. RxMed. VESANOID. Herndon, VA: RxMed. http://www.rxmed.com/b.main/b2.pharmaceutical/b2.1.monographs/CPS-%20Monographs/CPS-%20(General%20Monographs-%20V)/VESANOID.html. Accesses 11 Dec 2008.

  55. Horton TM, Pati D, Plon SE, Thompson PA, Bomgaars LR, Adamson PC, et al. A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children’s Oncology Group study. Clin Cancer Res. 2007;13:1516–22.

    Article  PubMed  CAS  Google Scholar 

  56. Tedesco Silva H Jr, Felipe CR, Machado PG, Garcia R, Motegi S, Hosaka BH, et al. Safety and efficacy of sirolimus in kidney transplant patients and in patients with coronary artery disease undergoing angioplasty. Transplant Proc. 2003;35:177S–80S.

    Article  PubMed  CAS  Google Scholar 

  57. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89:3354–60.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The excellent technical assistance of Inge Fink (cell culture, iodide uptake, thymidine uptake, and western blot) and of Elke Maier (immunocytochemistry) is gratefully acknowledged.

Author information

Authors and Affiliations

  1. Department of Endocrinology, Metabolism, Nephrology and Clinical Chemistry, Internal Medicine, University of Tuebingen, Otfried-Muellerstrasse 10, 72076, Tuebingen, Germany

    Eleonore Fröhlich & Richard Wahl

  2. Department of Haematology, Oncology, Immunology and Rheumatology, Internal Medicine, University of Tuebingen, Otfried-Muellerstrasse 10, 72076, Tuebingen, Germany

    Peter Brossart

  3. Department IV, Internal Medicine, Otfried-Muellerstrasse 10, 72076, Tuebingen, Germany

    Richard Wahl

Authors
  1. Eleonore Fröhlich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Brossart
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard Wahl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard Wahl.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fröhlich, E., Brossart, P. & Wahl, R. Induction of iodide uptake in transformed thyrocytes: a compound screening in cell lines. Eur J Nucl Med Mol Imaging 36, 780–790 (2009). https://doi.org/10.1007/s00259-008-1024-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-008-1024-6

Keywords

Search

Navigation